



**As long
as there
are unmet
needs,
we keep
working.**

We are dedicated to finding new treatments that will address the needs of those living with a central nervous system (CNS) disorder and to change the future of cancer care through precision-targeted approaches, including emerging modalities such as radiopharmaceutical therapy.

We're SK Life Science, and we won't rest.

About SK Life Science, Inc.

We are a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., the first and only Korean company to develop, commercialize and market an innovative drug in the U.S., the world's largest pharmaceuticals and biotech market.

We have a unique understanding of CNS disorders and the market-specific dynamics that impact the development and commercialization of new treatments.

Since 2017, SK Biopharmaceuticals has been strategically diversifying beyond CNS to invest in oncology, including emerging precision-targeted approaches such as radiopharmaceutical therapy, helping us become a stronger company that builds upon our success.

SK Life Science and SK Biopharmaceuticals are part of SK Group, a global leader with a tradition of promoting game-changing businesses and nurturing them for long-term success. As SK Group continues to expand its commitment to data-driven innovation, we are exploring how AI can further strengthen drug discovery and clinical development. SK Group was named one of TIME's 100 Most Influential Companies of 2023.

Our Purpose

We believe there is more to life when you connect health with happiness.

Our Vision

Together, we...

- Empower Excellence
- Embody a Pioneering Spirit
- Always Do the Right Thing
- Appreciate & Recognize People
- Inspire Happiness!

Shining a Light on the Treatment of CNS Disorders and Cancer Care

SK Life Science is here listening to the needs of healthcare providers, patients, caregivers, advocates, and scientists. We are developing new molecules, enhancing advocacy efforts, and providing solutions that change what's possible in the treatment of CNS disorders and cancer care. As our pipeline evolves, we are also exploring AI-enabled approaches to research and development to help address complex diseases with greater accuracy.

Committed to Next Generation Discovery


We have a deep expertise in research and development, as well as in bringing therapies to market in the U.S. We apply this expertise to the development of potential new therapies in CNS, while continuing to expand our capabilities into emerging areas of oncology.

Together, SK Biopharmaceuticals and SK Life Science, have multiple compounds in development in CNS and oncology. With a commitment to safety, we place our patients at the center of everything we do. To address the needs of people living with a central nervous system (CNS) disorder, we are currently enrolling patients in clinical trials.

Learn more about our pipeline at:
www.sklifescienceinc.com/innovation/#pipeline

Key Milestones in Our History

SK Biopharmaceuticals and SK Life Science independently developed an anti-seizure medication from inception through FDA approval.



More than 220,000 patients have been treated with our drug globally.

Data on file.

In the U.S., our ASM is the **fastest-growing branded epilepsy Rx** and is first among epileptologists.

According to NPA TRx 2023 vs 2022.



a subsidiary of SK biopharmaceuticals

Contact Us

For more information, visit us at:

www.sklifescienceinc.com